UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. ___)

VistaGen Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value \$0.001 per share

(Title of Class of Securities)

92840H202

(CUSIP Number)

December 31, 2020

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[X] Rule 13d-1(b)

[] Rule 13d-1(c)

[] Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Names of Reporting Persons. Acuta Capital Partners, LLC						
Check the Appropriate Box if a Member of a Group (See Instructions) (a) [X] (b) []						
	SEC Use Only					
Delaware	Citizenship or Place of Organization					
	-0-	Sole Voting Power	5.	Number of		
	7, 500 ,000 ⁽¹⁾	Shared Voting Power	6.	Number of Shares Beneficially		
	-0-	Sole Dispositive Power	7.	Owned by Each Reporting Person With:		
	7,500,000 ⁽¹⁾	Shared Dispositive Power	8.			
7,500,000 ⁽¹⁾	Aggregate Amount Beneficially Owned by Each Reporting Person			9.		
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)				10.		
Percent of Class Represented by Amount in Row (9) 5.4			11.			
Type of Reporting Person (See Instructions) OO, I			12.			

⁽¹⁾ Excludes an aggregate of 240,741 shares of Series D Convertible Preferred Stock that will become convertible into 5,537,043 shares of Common Stock upon approval of the Issuer's stockholders, subject to a 9.99% beneficial ownership limitation.

Page 2 of 7

1.	Names of Reporting Persons. Anupam Dalal					
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) [X] (b) []					
3.	SEC Use Only					
4.	4. Citizenship or Place of Organization		United States			
Number of	5.	Sole Voting Power	-0-			
Shares Beneficially Owned by Each Reporting Person With:	6.	Shared Voting Power	7,500,000 ⁽¹⁾			
	7.	Sole Dispositive Power	-0-			
	8.	Shared Dispositive Power	7,500,000 ⁽¹⁾			
9.	Aggregate Amount Beneficially Owned by Each Reporting Person7,500,0			7,500,000 ⁽¹⁾		
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)					
11.	Percent of Class Represented by Amount in Row (9) 5.49					
12.	Type of Reporting Person (See Instructions) IN, H					

⁽¹⁾ Excludes an aggregate of 240,741 shares of Series D Convertible Preferred Stock that will become convertible into 5,537,043 shares of Common Stock upon approval of the Issuer's stockholders, subject to a 9.99% beneficial ownership limitation.

Page 3 of 7

Item 1.

	(a)	Name of Issuer				
		VistaGen Therapeutics, Inc.				
	(b)	Address of Issuer's Principal Executive Offices 343 Allerton Avenue, South San Francisco, CA 94080				
Item 2.						
	(a)	The names of the persons filing this statement are:				
		Acuta Capital Partners LLC ("Acuta") and Dr. Anupam Dalal (collectively, the "Filers").				
		Each Filer disclaims beneficial ownership of the Stock except to the extent of that person's pecuniary interest therein.				
	(b)	The principal business office of the Filers is located at:				
		1301 Shoreway Road, Suite 350, Belmont, CA 94002				
	(c)	For citizenship of Filers, see Item 4 of the cover sheet for each Filer.				
	(d)	This statement relates to the Issuer's shares of Common Stock, par value \$0.001 per share (the "Stock").				
	(e)	The CUSIP number of the Issuer is: 92840H202.				
	Page 4 of 7					

Item 3.	If this s	statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:	
(a)	[]	Broker or dealer registered under section 15 of the Act (15 U.S.C. 780).	
(b)	[]	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).	
(c)	[]	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).	
(d)	[]	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).	
(e)	[X]	An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E) as to Acuta.	
(f)	[]	An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).	
(g)	[X]	A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G) as to Dr. Dalal.	
(h)	[]	A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).	
(i)	[]	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).	
(j)	[]	Group, in accordance with section 240.13d-1(b)(1)(ii)(J).	
Item 4.	Ownership.		

See Items 5-9 and 11 of the cover page for each Filer.

Item 5. **Ownership of Five Percent or Less of a Class**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [].

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

The funds managed by Acuta hold the Stock for the benefit of their investors and have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Stock.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Acuta is the general partner and investment adviser of investment funds. Dr. Dalal is the control person of Acuta.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification.

Certification:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Page 5 of 7

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 16, 2021

Acuta Capital Partners LLC

By: /s/ Scott R. Smith

Scott R. Smith, Chief Operating Officer

/s/ Anupam Dalal

Anupam Dalal

Page 6 of 7

EXHIBIT A

AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G

The undersigned agree to file jointly with the Securities and Exchange Commission (the "SEC") any and all statements on Schedule 13D, Schedule 13G or Forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint Acuta Capital Partners LLC, a Delaware limited liability company, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

Dated: February 16, 2021

Acuta Capital Partners LLC

By: /s/ Scott R. Smith

Scott R. Smith, Chief Operating Officer

/s/ Anupam Dalal Anupam Dalal

Page 7 of 7